Past
Sentinel lymph nodes normally are examined with ultra-staging, and non-sentinel nodes usually are examined only with routine technique. Low-volume metastasis (micrometastasis and isolated tumor cells) can be missed by classical pathologic analysis. For ability to consider the sentinel node technique as safe, clinicians must be sure that its negative predictive value (NPV) is 100%.
Present
To validate the sentinel lymph node technique from the low-volume metastasis point of view, the “Histopathological validation of sentinel lymph nodes study”,1 currently in press, included an ultra-staging examination of all nodes, sentinel nodes, and non-sentinel nodes of all Senticol 1 patients.2 To date, the discovery of these low-volume metastases can imply therapeutic decisions that can modify the patient’s management even if their clinical significance remains uncertain. This study1 can confirm that the NPV is 100% for optimal mapping with bilateral detection, which also is the low-volume metastasis point of view.
Anzeige
Future
The sentinel node technique is a safe technique. The future lies in standard use of the sentinel node technique for early-stage cervical cancer patients instead of lymphadenectomy. Clinicians are awaiting the results of Senticol 33 for definitive validation of this technique.
Disclosure
There are no conflicts of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
